International Conference on Personalized Oncology
12 October 2017
I.M.Sechenov First Moscow State Medical University, Moscow


Roger D. KAMM

Roger D. KAMM, PhD.
Professor of Biological and Mechanical Engineering; Cecil and Ida Green Distinguished Professor; Singapore Research Professor
Massachusetts Institute of Technology, USA

Roger Kamm is the Cecil and Ida Green Distinguished Professor of Biological and Mechanical Engineering at MIT. He is the recipient of the ASME Lissner Award (2010) and the European Society of Biomechanics Huiskes Medal (2015). He is a Fellow of the ASME, AIMBE, AAAS, and the IAMBE, and in 2010 was elected a member of the National Academy of Medicine. He is former Chair of the US National Committee on Biomechanics, the World Council on Biomechanics, and the International Academy of Medical and Biological Engineering. Kamm’s research group applies fundamental concepts in fluid and solid mechanics to better understand essential biological and physiological phenomena. His lab focuses on the molecular mechanisms of cellular force transmission and sensation, and the development of new microfluidic technologies for vascularized engineered tissues and models of metastatic cancer. He is co-founder of two companies, CardioVascular Technologies, and AIM Biotech, and is currently the Director of the NSF Science and Technology Center on Emergent Behaviors of Integrated Cellular Systems.


Chul - Woo KIM

Chul - Woo KIM, MD, PhD.
Founder and CEO of Bioinfra, Professor Emeritus of Pathology at Seoul National University (SNU), South Korea

Dr. Chul Woo Kim of the Department of Pathology of Seoul National University Hospital founded "Bioinfra" in 2001, and after 12 years of research, he developed Smart Cancer Screening Test, which is innovative method of detecting cancers.

  • Member of Korea Academy of Science & Technology (KAST), a prestigious society of technologically advanced experts and scientists.
  • Over 180 SCI papers on Medical & Science fields.
  • Former CEO of Korean Pathologist Association and Chairman of Department of Pathology at Seoul National University College of Medicine.
  • Visiting professor at Harvard Medical School.


Vladimir LAZAR

Vladimir LAZAR, MD, PhD
Founder, Chief Scientific and Operating Officer of the WIN Consortium

Dr. Vladimir Lazar obtained his MD (1989) at The University of Timisoara (Romania), First in Class and Certificate of Merit “Magna cum Laudae”. He became a specialist in Clinical Biology (DIS, 1977, University René Descartes in Paris) and obtained his PhD in molecular biology (1997) at The University René Descartes in Paris, with the highest degree and the Prize of University. Dr. Vladimir Lazar is specialized in clinical biology, molecular biology, molecular pathology and has a broad training, education and postgraduate degrees in biotechnology (first in class) and project management. He is recognized specialist in translating research to clinical applications. He was the founder and Head of Gustave Roussy’s Genomic Center and Integrated Biology Platform (2002-2015) running the Agilent European reference and training center. He is the founder and current Chief Operating officer of the WIN Consortium. In these positions he has built a strong expertise in project design, technology evaluation and implementation, use of genomics and biomarkers in oncology, companion test development, and biology driven clinical trials. He has also developed leadership and entrepreneurial skills through the creation of his initiatives.
He is author of 6 patents and author-co-author of more than 100 publications.



Director, Khalifa Institute for Personalized Cancer Therapy
Past President, UT M D Anderson Cancer Center

Dr. Mendelsohn has served as the Co-Director of the Khalifa Institute for Personalized Cancer Therapy at The University of Texas MD Anderson Cancer Center since September 2011.
Dr. Mendelsohn also served as President of the MD Anderson Cancer Center from 1996 to August 2011.
Prior to joining the MD Anderson Cancer Center, Dr. Mendelsohn was founding director of the cancer center at the University of California San Diego and served as Chairman of Medicine at Memorial Sloan-Kettering Cancer Center from 1985 to 1996.
Dr. Mendelsohn also currently serves as the L.E. and Virginia Simmons Senior Fellow in Health and Technology Policy at the James A. Baker, III Institute for Public Policy.
Dr. Mendelsohn is recognized for his research on the binding of growth factors to cell surface receptors and how they regulate cell functions, which led to the discovery, development and eventual commercialization of the cancer therapy cetuximab (Erbitux®).
Dr. Mendelsohn holds an M.D. from Harvard Medical School and a B.S. from Harvard College.



Shawn N. MURPHY, MD, PhD
Professor, Harvard Medical School, Corporate Director of Research Information Systems and Computing, Partners HealthCare and Massachusetts General Hospital, Boston, MA, USA

Dr. Murphy developed the Research Patient Data Registry (RPDR) for Partners HealthCare, a large data warehouse with 6 million patients and 2 billion rows of clinical data, serving as a central clinical data registry for inpatient and outpatient encounters in order to support clinical research. The RPDR brings clinical information to the fingertips of over 3,000 active researchers. Dr. Murphy is also the chief architect and software development manager for the NIH Sponsored Informatics for Integrating Biology and the Bedside (i2b2), an open source project that integrates data from the hospital medical record and the bioinformatics community into a common software platform, with over 100 operating installations worldwide.